|
Despite Lilly’s Phase III Alzheimer’s Stumbles, Analysts Hope for Filing
Eli Lilly’s Alzheimer’s disease candidate solanezumab failed to meet its primary endpoints in a pair of closely watched Phase III trials, but flickers of promise seen in mildly affected Alzheimer’s patients have lifted some analysts’ hopes the drug could still be filed for regulatory approval.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives